Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...
Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...
Please provide your email address to receive an email when new articles are posted on . Dulaglutide, semaglutide and tirzepatide had similar GI safety profiles. An increased risk for GI adverse events ...
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...
A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...
Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received ...
Hosted on MSN
Could this be the new Ozempic?
A new drug has shown promise as a type 2 diabetes and weight loss treatment—potentially offering an new rival to drugs like Ozempic. Ecnoglutide—a new once-weekly GLP-1 receptor agonist injection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback